CIK 0000921299
- Non-accelerated filer
- Smaller reporting company
KYNTRA BIO, INC.
Sign in to watch- Ticker
- KYNB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770357827
- Phone
- +1 415-978-1200
- Business address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
- Former names
- FIBROGEN INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-06 | Wettig Thane Chief Commercial Officer | Shares withheld for taxes | −360 | $9.50 | $3K | 89,961 |
| 2022-06-01 | Eisner Mark Chief Medical Officer | Shares withheld for taxes | −1,141 | $9.61 | $11K | 149,800 |
| 2022-04-07 | Conterno Enrique A Chief Executive Officer | Shares withheld for taxes | −1,311 | $12.73 | $17K | 303,712 |
| 2022-03-31 | Chung Christine SVP, China Operations | Shares withheld for taxes | −4,682 | $12.02 | $56K | 245,852 |
| 2022-03-31 | Eisner Mark Chief Medical Officer | Shares withheld for taxes | −6,442 | $12.02 | $77K | 150,941 |
| 2022-03-22 | Wettig Thane Chief Commercial Officer | Shares withheld for taxes | −655 | $13.31 | $9K | 90,321 |
| 2022-03-07 | Wettig Thane Chief Commercial Officer | Shares withheld for taxes | −1,706 | $12.69 | $22K | 90,976 |
| 2022-03-07 | Chung Christine SVP, China Operations | Shares withheld for taxes | −3,905 | $12.69 | $50K | 250,534 |
| 2022-03-07 | Conterno Enrique A Chief Executive Officer | Shares withheld for taxes | −7,081 | $12.69 | $90K | 305,023 |
| 2022-03-01 | Eisner Mark Chief Medical Officer | Shares withheld for taxes | −756 | $13.62 | $10K | 157,383 |
| 2022-02-14 | Wettig Thane Chief Commercial Officer | Grant or award | +45,000 | 92,682 | ||
| 2022-02-14 | Wettig Thane Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-02-14 | Graham Juan Chief Financial Officer | Grant or award | +22,500 | 58,900 | ||
| 2022-02-14 | Graham Juan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2022-02-14 | Eisner Mark Chief Medical Officer | Grant or award | +60,000 | 158,139 | ||
| 2022-02-14 | Eisner Mark Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2022-02-14 | Chung Christine SVP, China Operations | Grant or award | +45,000 | 254,439 | ||
| 2022-02-14 | Chung Christine SVP, China Operations | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-02-14 | Conterno Enrique A Chief Executive Officer | Grant or award | +179,400 | 312,104 | ||
| 2022-02-14 | Conterno Enrique A Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +298,000 | 298,000 |
Page 13 of 16 · 320 trades